Gentium S.p.A. (ADR) (NASDAQ:GENT)
| CAPS Rating |
|
|---|---|
| Open | $9.04 |
| Previous Close | $9.20 |
| Daily Range | $8.25 - $9.04 |
| 52-Week Range | $5.31 - $13.69 |
| Market Cap | $127.21M |
| P/E Ratio | 15.20 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 37,555 |
| Average Daily Volume | 0 |
GENT
VS S&P 500 (SPY)
How do you think GENT will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
GENT Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
GENT News and Commentary
- Italian Mess: Does Berlusconi Really Matter? – NASDAQ
- Market Risks: Now, Everyone Start Freaking Out About Italian Debt – NASDAQ
- Italy's a Mess – The Motley Fool
- Mama Mia! Keep an Eye on These Italian Stocks – NASDAQ
- 19 Undervalued Microcaps With EPS Growth of Over 50% for 2011-12 – SeekingAlpha
- 19 Undervalued Micro Caps With EPS Growth of Over 50% for 2011-12 – SeekingAlpha
- Gentium Swings to Q3 Profit as Drug Sales Jump 97% – SeekingAlpha
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Life Technologies' Sequence of Success – The Motley Fool
- Is Avanir Pharmaceuticals the Perfect Stock? – The Motley Fool
- Can Amgen Convince Docs to Recommend Approval? – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- Curing Diseases Makes For a Bad Business Model – The Motley Fool
- Idenix Pharmaceuticals Shares Dropped: What You Need to Know – The Motley Fool
- What's Going on With These Biotech Stocks? – The Motley Fool
- Gilead Sciences Shares Surged: What You Need to Know – The Motley Fool
RSS Headlines
Fool UK
